Table 1.

Best overall response for patients with AML at any time on treatment

Best overall response, n (%)	Glasdegib + LDAC N = 78	LDAC alone N = 38
Achieved CR
CR	15 (19.2)	1 (2.6)
Did not achieve CR
CRi	4 (5.1)	1 (2.6)
PR	5 (6.4)	0
PRi	2 (2.6)	0
MLFS	2 (2.6)	0
MR	4 (5.1)	4 (10.5)
SD	14 (17.9)	9 (23.7)
Treatment failure	9 (11.5)	7 (18.4)
Not evaluable	23 (29.5)	16 (42.1)

AML acute myeloid leukemia, CR complete remission, CRi CR with incomplete hematologic recovery, LDAC low-dose cytarabine, MLFS morphologic leukemia-free state, MR minor response, PR partial remission, PRi PR with incomplete hematologic recovery, SD stable disease